drugset / Trial / NCT01901679

Celecoxib Inhibition of Aromatase Expression and Inflammation in Adipose Tissue of Obese Postmenopausal Women

NCT01901679

Phase 0 Completed 10 enrolled Rockefeller University
NaSingle-groupOpen-labelBasic science

Summary

The study plans to find out whether Celebrex may be potentially useful to decrease inflammation in fat tissues and thereby lower the production of substances such as estrogens that may increase the risk of developing breast cancer and lead to a poor outcome of the disease.

Timeline

Start
2013-07
Primary completion
2014-08
Completion
2014-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified 200 mg Oral

Indications